Holdouts also challenged a claim from J&J and its supporters that the settlement is backed by more than 80% of claimants.

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 ...

J&J said that about a third of adults will not respond to oral antidepressants alone. Sign up here to get The Results Are In with Dr. Sanjay Gupta every Friday from the CNN Health team.

J&J will also be looking for growth from newer medicines including Tecvayli and Talvey. Outside of oncology, J&J’s depression treatment Spravato brought in sales of $1.1 billion for the year, a 56% ...

J&J provided its estimate of the redesign’s financial impact Wednesday alongside earnings for the fourth quarter. In doing so, the company follows Pfizer, which late last year forecast the changes ...

From a chaotic upbringing in poverty to bestselling author, U.S. senator and now vice president-elect of the United States, J.D. Vance has walked a winding, often contradictory road to his seat ...

Year-end highlights in metastatic triple-negative breast cancer from the 2022 American Society of Clinical Oncology Annual Meeting, and the European Society for Medical Oncology Congress and ...